Wedbush
Wedbush Securities is a privately held brokerage, clearing and investment banking firm based in Pasadena, California, whose equity research covered about 300 stocks as of 2025 across technology and media, life sciences, and financial institutions and real estate.
Activity24M
RatingsPrice targetsKey figures
- Stocks covered
- 25412M
- Actions
- 1,12712M
- Ratings / Price targets
- 760 / 367
- Upgrades / Downgrades
- 15 / 41
- Initiations
- 11
- Buy-rated
- 72%of 238 rated
- Median upside
- +23.1%
- Targets raised / lowered
- 178 / 89
- On record
- Feb 2012 – Sep 2026
Overview
In 2025, Wedbush's fund management arm launched the IVES ETF using research on 30 AI companies by Dan Ives, who led the firm's technology research until 2026. Wedbush publishes daily notes, thematic reports and earnings previews.
Edward W. Wedbush and Robert Werner founded Wedbush & Company in Los Angeles in 1955; Werner sold his stake in 1960. The firm bought Noble, Cooke & Co. in 1969, joined the NYSE in 1971, began clearing for other firms in 1972 and bought William R. Staats & Co. in 1975. It acquired Morgan, Olmstead, Kennedy & Gardner in 1988 and traded as Wedbush Morgan Securities until 2010, then moved its headquarters to Pasadena in 2025.
Milestones
- 1955
Founded by Edward Wedbush and Robert Werner in Los Angeles
- 1969
Acquired Noble, Cooke & Co., entering wholesale business
- 1971
Became a New York Stock Exchange member
- 1988
Acquired Morgan, Olmstead, Kennedy & Gardner
- 2010
Renamed Wedbush Securities from Wedbush Morgan Securities
- 2025
Moved headquarters from downtown Los Angeles to Pasadena
Firm facts
- Legal name
- Wedbush Securities Inc.
- Type
- Full-service
- Founded
- 1955
- Headquarters
- Pasadena, United States
- Parent
- Wedbush Financial Services
- President & CEO
- Gary Wedbush
- Director of Research
- Seth Basham
- Rating scale
- OutperformNeutralUnderperform6–12 months
- Website
- wedbush.com
Research philosophy
We produce original thought, proprietary research products, and highlight critical data points, which anticipate early industry trends and inflection points.
Wedbush describes its equity research as focused on delivering alpha. Chief executive Gary Wedbush said in 2026 that the firm sets itself apart by letting distinctive talents develop their own voice and brand.
Rating methodology
Ratings are Outperform, Neutral and Underperform, measured against the median total return of the analyst's coverage universe over 6–12 months; the firm adopted this scale in July 2009, replacing Strong Buy, Buy, Hold and Sell.
Coverage12M
Sectors
Most covered24M
| Stock | Rating | Target |
|---|---|---|
 Tesla, Inc.TSLA | Outperform | $600 |
 Apple Inc.AAPL | Outperform | $400 |
 Micron Technology, Inc.MU | Neutral | $1,400 |
 Roblox CorporationRBLX | Neutral | $48 |
 Amazon.com, Inc.AMZN | Outperform | $310 |
 argenx SEARGX | Outperform | $1,150 |
 Revolution Medicines, Inc.RVMD | Outperform | $201 |
 Advanced Micro Devices, Inc.AMD | Outperform | $290 |
 Logitech International S.A.LOGI | Outperform | $130 |
 NVIDIA CorporationNVDA | Underperform | $330 |
Most active analysts
- Daniel Ives49 notesPLTRTSLAESTC
- Scott Devitt20 notesGOOGLGOOGDASH
- David Nierengarten18 notesCOAGANABNTLA
- Laura Chico17 notesDNLIJBIOLRMR
- Matt Bryson15 notesMUINTCAMD
- Robert Driscoll11 notesPYXSREPLTYRA
Recent actions
| Date | Stock | Rating action | Rating | Target | Analyst |
|---|---|---|---|---|---|
| Sep 22 | CMCompass Therapeutics, Inc.CMPX | Downgrade | Neutral | $1 | Robert Driscoll |
| Sep 22 |  Abivax S.A.ABVX | Reiterate | Neutral | $90 →$118 | |
| Sep 22 | TVTravere Therapeutics, Inc.TVTX | Reiterate | Outperform | ||
| Sep 18 | XEXenon Pharmaceuticals Inc.XENE | Reiterate | Outperform | $42 →$55 | |
| Sep 18 | FUfuboTV Inc.FUBO | Reiterate | Outperform | ||
| Sep 16 |  Rocket Pharmaceuticals, Inc.RCKT | Reiterate | Outperform | ||
| Sep 16 | COCogent Biosciences, Inc.COGT | Reiterate | Outperform | ||
| Sep 16 | NUNuvation Bio Inc.NUVB | Reiterate | Outperform | ||
| Sep 15 | BNBenitec Biopharma Inc.BNTC | Target | $16 →$17 |